Inactive Instrument

TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index CI
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index CI
Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders. CI
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Mizuho Securities Downgrades TCR2 Therapeutics to Neutral From Buy, Adjusts Price Target to $1.72 From $20 MT
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating MT
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Jobs Report -3- DJ
Jefferies Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $18 MT
North American Morning Briefing : Stock Futures -3- DJ
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8 MT
HC Wainwright Downgrades TCR2 Therapeutics to Neutral From Buy MT
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating MT
Sector Update: Health Care Stocks Hit by Late Selling MT
Top Midday Decliners MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Back on Positive Ground MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday MT
Upcoming Powell Testimony to Congress Underpins US Equity Futures MT
Top Premarket Decliners MT
Top Premarket Gainers MT
Adaptimmune Therapeutics, TCR2 Therapeutics to Merge in All-Stock Transaction MT
Adaptimmune and TCR2 Therapeutics Inc. Announce Strategic Combination to Create Preeminent Cell Therapy Company for Solid Tumors CI
Adaptimmune Therapeutics plc entered into a definitive agreement to acquire TCR2 Therapeutics Inc. from a group of shareholders for approximately $110 million. CI
Chart TCR2 Therapeutics Inc.
More charts
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company's TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
More about the company